1. Evt 201
2. Evt-201
3. Evt201
1. Evt-201
2. 308239-86-3
3. 6j8af7cle4
4. Unii-6j8af7cle4
5. Evt201
6. Schembl3088188
7. Dtxsid301032055
8. Q19597232
9. 6h-imidazo(1,5-a)(1,4)benzodiazepin-6-one, 7-chloro-3-(5-((dimethylamino)methyl)-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-methyl-
10. 7-chloro-3-(5-dimethylaminomethyl-[1,2,4]oxadiazol-3-yl)-5-methyl-4,5-dihydro-imidazo[1,5-a][1,4]benzodiazepin-6-one
| Molecular Weight | 372.8 g/mol |
|---|---|
| Molecular Formula | C17H17ClN6O2 |
| XLogP3 | 1.2 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 3 |
| Exact Mass | 372.1101515 g/mol |
| Monoisotopic Mass | 372.1101515 g/mol |
| Topological Polar Surface Area | 80.3 Ų |
| Heavy Atom Count | 26 |
| Formal Charge | 0 |
| Complexity | 537 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in insomnia.
In two Phase I/II studies using the traffic noise model of insomnia in healthy male volunteers, EVT 201 significantly reduced "wake after sleep onset" (WASO) while significantly increasing "total sleep time" (TST) and quality of sleep with no subjective residual effects. The compound was well tolerated without significant adverse events.
EVT 201 is a partial positive allosteric modulator (pPAM) of the GABAA receptor complex and consequently works through a proven pathway in the treatment of insomnia. However, EVT 201s partial agonist activity gives it a differentiated pre-clinical profile and mechanism of action compared to many currently marketed sleep-promoting agents.
